Molecular therapies targeting EGFR have been developed in recent years, such as gefitinib, but many patients do not respond well to EGFR inhibitors, including those with non-small-cell lung cancer or glioblastoma [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.